Loading…
CO-AMOXICLAV is a brand name for Amoxicillin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Co-amoxiclav is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1): • Acute bacterial sinusitis (adequately diagnosed) • Acute otitis media • Acute exacerbations of chronic bronchitis (adequately diagnosed) • Community acquired pneumonia • Cystitis •…
Verbatim from this product's MHRA label. Tap a section to expand.
Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component. 4) • The severity and the site of the infection • The age, weight and renal function of the patient as shown below.
g. 1). For children < 40 kg, this formulation of Co-amoxiclav provides a maximum daily dose of 2400 mg amoxicillin/600 mg clavulanic acid, when administered as recommended below. 1). The duration of therapy should be determined by the response of the patient.
g. osteomyelitis) require longer periods of treatment. 4 regarding prolonged therapy). Adults and children 40 kg should be treated with the adult formulations of co-amoxiclav. Children < 40 kg Lower dose: 20mg/5mg/kg/day to 40 mg/10 mg/kg/day given in three divided doses.
Higher dose: 40mg/ 10 mg/kg/day to 60 mg/kg/day given in three divided doses. Body weight (kg) 20mg/5 mg/kg/day. Dose in ml to be given every 8 hours 40mg/10 mg/kg/day. Dose in ml to be given every 8 hours 60mg/15 mg/kg/day. 2
2 NR – Not recommended. No clinical data are available on doses of Co- Amoxiclav 4:1 formulations higher than 40mg/ 10mg/ kg per day in children under 2 years. Alternative oral formulations of co-amoxiclav should be considered to deliver practical dose recommendations.
Children may be treated with Co-amoxiclav tablets, suspensions or paediatric sachets. Children aged 6 years and below should preferably be treated with Co-amoxiclav suspension or paediatric sachets. The dose (ml) to be given to the patient three times daily can also be calculated using the following formula below: *Only consideration of the amoxicillin component is required for this calculation.
For example, a 6 kg child treated at 20 mg/5 mg/kg/day:
Elderly No dose adjustment is considered necessary. Elderly patients should be treated with adult formulations of Co-amoxiclav. Renal impairment Dose adjustments are based on the maximum recommended level of amoxicillin. No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.
75 mg/kg twice daily (maximum 500 mg/125 mg twice daily). 75 mg/kg as a single daily dose (maximum 500 mg/125 mg). 75 mg/kg per day once daily. 75 mg/kg. 75 mg per kg should be administered after haemodialysis. 4). Method of administration Co-amoxiclav is for oral use.
Co-amoxiclav should be administered with a meal to minimise gastrointestinal intolerance. Space the doses evenly during the day, at least 4 hours apart. Shake to loosen powder, add water as directed, invert and shake. 6). 6. 3 Contraindications Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.
g. g. a cephalosporin, carbapenem or monobactam). 8). 8). Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. 8).
2 NR – Not recommended. No clinical data are available on doses of Co- Amoxiclav 4:1 formulations higher than 40mg/ 10mg/ kg per day in children under 2 years. Alternative oral formulations of co-amoxiclav should be considered to deliver practical dose recommendations.
Children may be treated with Co-amoxiclav tablets, suspensions or paediatric sachets. Children aged 6 years and below should preferably be treated with Co-amoxiclav suspension or paediatric sachets. The dose (ml) to be given to the patient three times daily can also be calculated using the following formula below: *Only consideration of the amoxicillin component is required for this calculation.
For example, a 6 kg child treated at 20 mg/5 mg/kg/day:
Elderly No dose adjustment is considered necessary. Elderly patients should be treated with adult formulations of Co-amoxiclav. Renal impairment Dose adjustments are based on the maximum recommended level of amoxicillin. No adjustment in dose is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.
75 mg/kg twice daily (maximum 500 mg/125 mg twice daily). 75 mg/kg as a single daily dose (maximum 500 mg/125 mg). 75 mg/kg per day once daily. 75 mg/kg. 75 mg per kg should be administered after haemodialysis. 4). Method of administration Co-amoxiclav is for oral use.
Co-amoxiclav should be administered with a meal to minimise gastrointestinal intolerance. Space the doses evenly during the day, at least 4 hours apart. Shake to loosen powder, add water as directed, invert and shake. 6). 6. 3 Contraindications Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.
g. g. a cephalosporin, carbapenem or monobactam). 8). 8). Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. 8).
Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients. g. g. a cephalosporin, carbapenem or monobactam). 8).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Amoxicillin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.
8). DIES is an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after drug use) in the absence of allergic skin or respiratory symptoms. Further symptoms could comprise abdominal pain, diarrhoea, hypotension or leucocytosis with neutrophilia.
There have been severe cases including progression to shock. In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.
This presentation of Co-amoxiclav is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid.
This presentation should not be used to treat penicillin-resistant S. pneumoniae. 8). Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.
Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. Prolonged use may occasionally result in overgrowth of non-susceptible organisms. 8). This reaction requires Co-amoxiclav discontinuation and contra-indicates any subsequent administration of amoxicillin.
8). Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually […]
These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.
8). DIES is an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after drug use) in the absence of allergic skin or respiratory symptoms. Further symptoms could comprise abdominal pain, diarrhoea, hypotension or leucocytosis with neutrophilia.
There have been severe cases including progression to shock. In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.
This presentation of Co-amoxiclav is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid.
This presentation should not be used to treat penicillin-resistant S. pneumoniae. 8). Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.
Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. Prolonged use may occasionally result in overgrowth of non-susceptible organisms. 8). This reaction requires Co-amoxiclav discontinuation and contra-indicates any subsequent administration of amoxicillin.
8). Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and […]